Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valproic Acid With Methylprednisolone for Acute GVHD
NCT02848105Phase 2
Key facts
- Status
- Unknown
- Start
- Jul 2016
- Primary completion
- Jul 2019
- Countries
- 1
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Modality
- Small Molecules
- Drugs
- valproic acid
- Conditions
- Acute Graft-Versus-Host Disease (aGvHD)
01
Overview
Phase 2, open-label, single-arm trial of valproic acid in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Complete Response at 28 days. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
VPA+Methyl
Valproic acid added to standard methylprednisolone
03
Who it enrols
Patients with Grade II-IV aGVHD after allogeneic stem cell transplantation, without severe organ dysfunction or active severe infection.
04
Endpoints
Primary
Complete Response
Secondary
Overall Response
Beyond the preview
Go deeper on NCT02848105.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02848105.